Crossmark

Dopamine agonist resistant prolactinomas: any alternative medical treatment?

Crossref DOI link: https://doi.org/10.1007/s11102-019-00987-3

Published Online: 2019-09-14

Published Print: 2020-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Souteiro, P. https://orcid.org/0000-0002-1359-814X
Karavitaki, N. https://orcid.org/0000-0002-4696-0643
License Information

Text and Data Mining valid from 2019-09-14

Version of Record valid from 2019-09-14
More Information

Article History

First Online: 14 September 2019

Compliance with ethical standards

:

: N. Karavitaki has received educational and research Grants from Novartis, Pfizer and Ipsen.